RegulatoryCompany release

Beta Bionics withdraws 3D Intelligence 510(k) after FDA talks; Mint device cleared

🇺🇸 Beta Bionics, Inc. (BBNX) · Tue 27 Oct 2026

The insulin pump maker plans to resubmit its dosing algorithm in mid-Q4 2026 with added simulator data, while winning FDA clearance for Mint.

Beta Bionics has withdrawn its 510(k) premarket notification for the 3D Intelligence insulin dosing algorithm following interactions with the US Food and Drug Administration. The company disclosed the move on 27 October 2026 alongside its third-quarter results.

The company intends to resubmit the application around the middle of the fourth quarter of 2026. The new submission will include additional validation data generated using a simulator. The summary available does not specify what questions the FDA raised or what form the added data will take.

Beta Bionics also announced that the FDA has cleared its Mint device. The company expects a full US launch in the first quarter of 2027. No further details on the device's specifications or indication were provided in the material reviewed.

Looking further ahead, Beta Bionics said it expects to seek an expanded indication for its iLet system for adults with type 2 diabetes at around mid-2027. As general context, a 510(k) is the US pathway through which a device is cleared by showing substantial equivalence to a legally marketed predicate, and a sponsor can withdraw and refile a submission.

What it means for your team

  • Regulatory teams should note that the 3D Intelligence algorithm will not be cleared on the original submission; the resubmission timeline of mid-Q4 2026 is the next milestone to watch.
  • The planned addition of simulator validation data suggests that evidence supporting dosing algorithms is a focus of FDA interactions, although the specific deficiencies have not been disclosed.
  • Market-access and commercial planners can use the Q1 2027 full US launch of Mint and the mid-2027 type 2 diabetes iLet filing plan as reference dates, subject to FDA review outcomes.

Company's press release (SEC filing): Beta Bionics, Inc. ↗

Article written by VigiEye from the official source (Beta Bionics, Inc.). Claims are the company's own. AI-assisted; check the source before acting.

More Regulatory All →